Hematology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed advantages of OTQ923 in treating SCD.

Poolbeg Pharma’s POLB 001 previously showed promise in a lipopolysaccharide human challenge trial.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Co-Founder, Executive Vice President, and Chief Medical Officer, CLL Society, discussed the role the society plays in the field.

Review top news and interview highlights from the week ending January 13, 2023.

The chief medical and scientific officer of Tessa Therapeutics discussed data from the BESTA and CHARIOT studies presented at ASH 2022.

The assistant member of the bone marrow transplantation and cellular therapy department at St. Jude Children’s Hospital discussed preclinical research presented at ASH 2022.

Athersys has made progress in enrollment with its MATRICS-1 and MASTERS-2 clinical trials.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.

The assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.

The new analysis data was requested by the FDA ahead of the therapy’s March 31, 2023 PDUFA date.

Brent Warner, president, gene therapy, Poseida Therapeutics, discussed data on the preclinical P-FVIII-101 presented at ASH 2022.

CKO804 is being evaluated as an add-on therapy to ruxolitinib in patients whose disease had a suboptimal response to ruxolitinib alone.

The first patient dosed in the study experienced a case of prolonged pancytopenia that has required ongoing transfusion and growth factor support.

Review top news and interview highlights from the week ending January 6, 2023.

Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.

Allocetra previously demonstrated efficacy in a phase 1b trial for patients with sepsis.

The associate professor of medicine from University of Pennsylvania discussed updated data on huCART19-IL18 presented at the ASH 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CT103A is currently being evaluated in multiple clinical trials in China.

The assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.

The BALLI-01 study, initiated in 2019, has now dosed its first patient with an in-house manufactured CAR T-cell therapy candidate.

The company is seeking out other companies to continue development of its autologous CAR-T platform.